Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Samid, D.
Right arrow Articles by Thibault, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Samid, D.
Right arrow Articles by Thibault, A.
Clinical Cancer Research Vol. 6, 933-941, March 2000
© 2000 American Association for Cancer Research

Experimental Therapeutics, Preclinical Pharmacology

Peroxisome Proliferator-activated Receptor {gamma} as a Novel Target in Cancer Therapy: Binding and Activation by an Aromatic Fatty Acid with Clinical Antitumor Activity1

Dvorit Samid2, Michelle Wells, Marianne E. Greene, Weiyin Shen, Colin N. A. Palmer and Alain Thibault

University of Virginia Health Sciences Center, Charlottesville, Virginia 22908 [D. S., M. W., W. S., A. T.]; Children’s Memorial Medical Center, Northwestern University School of Medicine, Chicago, Illinois 60614 [M. E. G.]; and Biomedical Research Center and Imperial Cancer Research Fund Pharmacology Unit, Ninewells, Hospital and Medical School, University of Dundee, Dundee DD1 9SY, United Kingdom [C. N. A. P.]


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Aromatic fatty acids, of which phenylacetate is a prototype, constitute a class of low toxicity drugs with demonstrated antitumor activity in experimental models and in humans. Using in vitro models, we show here a tight correlation between tumor growth arrest by phenylacetate and activation of peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}), a member of the nuclear receptor superfamily. In support are the following observations: (a) the efficacy of phenylacetate as a cytostatic agent was correlated with pretreatment levels of PPAR{gamma}, as documented using established tumor lines and forced expression models; (b) in responsive tumor cells, PPAR{gamma} expression was up-regulated within 2–9 h of treatment preceding increases in p21waf1, a marker of cell cycle arrest; (c) inhibition of mitogen-activated protein kinase, a negative regulator of PPAR{gamma}, enhanced drug activity; and (d) phenylacetate interacted directly with the ligand-binding site of PPAR{gamma} and activated its transcriptional function. The ability to bind and activate PPAR{gamma} was common to biologically active analogues of phenylacetate and corresponded to their potency as antitumor agents (phenylacetate < phenylbutyrate < p-chloro-phenylacetate < p-iodo-phenylbutyrate), whereas an inactive derivative, phenylacetylglutamine, had no effect on PPAR{gamma}. These findings point to PPAR{gamma} as a novel target in cancer therapy and provide the first identification of ligands that have selective antitumor activity in patients.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The search for compounds that can reverse the characteristic cellular dedifferentiation of neoplasms, inhibit their growth, and hence be added to the therapeutic armamentarium has led to the identification of aromatic fatty acids as a promising new class of antitumor agents (1 , 2) . The prototypic compound, PA,3 is a naturally occurring growth regulator highly conserved in evolution. In experimental models, the aromatic fatty acids induce cytostasis and differentiation of various hematological and solid neoplasms, including multidrug resistant tumors (1 , 3, 4, 5, 6, 7, 8) . Early clinical trials with PA documented activity in high-grade gliomas, hormone-independent prostatic carcinoma, and lymphoid malignancies (1 , 9, 10, 11) .4 PB, which is metabolized to PA in humans, was also shown recently to benefit cancer patients who have failed conventional therapies (12, 13, 14, 15) . For both drugs, large drug doses are required to reach therapeutic plasma concentrations (mM range); these are well tolerated, with the dose-limiting toxicity being somnolence. The mechanisms of action are, however, unclear.

In the preclinical models, changes in tumor biology induced by PA and PB have consistently been associated with alterations in lipid metabolism, exemplified by the intracellular accumulation of fat droplets and by declines in cholesterol synthesis. The latter are accompanied by major changes in gene expression occurring at both the transcriptional and posttranslational levels. Declines in protein prenylation appear to be attributable to inhibition of mevalonate-PP decarboxylase, a key enzyme controlling the mevalonate pathway of de novo cholesterol metabolism (3 , 16) . Changes in gene transcription, on the other hand, have been linked to increased DNA availability for interaction with transcriptional factors through inhibition of histone deacetylation (17) and of DNA methylation (18) . Our studies aiming to identify transcriptional factors involved have recently documented the activation of PPAR{alpha} (19) , a member of the nuclear hormone receptor superfamily implicated in growth control and differentiation.

PPAR{alpha} is one of three distinct gene isoforms isolated to date from human cells; the other two are designated PPAR{gamma} and PPAR{delta} (also known as NUC1 and PPARß; Refs. 20 and 21 ). These are ligand-activated transcriptional factors capable of interacting with genes that contain consensus PPRE as a direct repeat of two AGGTCA half-sites separated by a single intervening nucleotide (DR-1). PPARs recognize their cognate response element through heterodimerization with the retinoid X receptor {alpha}, a characteristics shared with their closely related nuclear receptors activated by retinoids (retinoic acid receptors), vitamin D (vitamin D receptor), and thyroid hormone (thyroid receptor). Among the compounds known to activate PPAR{alpha} are fibrate hypolipidemic agents. Considering the structural similarity to clofibrate, we first examined the effect of PA and its analogues on PPAR{alpha}. The aromatic fatty acids were found to stimulate the production and transcriptional function of the nuclear receptor, and the effect was correlated with their potency as inhibitors of tumor cell proliferation. Our earlier findings indicating that PA is a very effective inducer of adipocyte differentiation (1) , a biological process dependent on PPAR{gamma} activation (22) , led us to expand the scope of our investigation and speculate that this nuclear receptor subtype might also be a target of anticancer therapy.

The studies reported herein were thus undertaken to examine the effect of PA on PPAR{gamma} in human tumor cells. Using breast carcinoma and glioma cultures, we show here that pharmacological concentrations of PA increase PPAR{gamma} expression and transcriptional function and provide evidence for a biological role of this nuclear receptor in tumor cytostasis induced by aromatic fatty acids.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Cultures and Reagents.
MCF7 and MCF7ADR breast carcinoma lines were obtained from Dr. Richard Camalier (National Cancer Institute, Frederick, MD). The glioblastoma lines A172 and U251 and the monkey kidney CV-1 cells were purchased from the American Type Culture collection (Rockville, MD). Cultures of human tumor cells were maintained in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, and 0.1% penicillin, streptomycin, neomycin antibiotics (Life Technologies, Inc., Gaithersburg, MD).The growth medium for CV-1 was DMEM (Life Technologies). The sodium salts of PA and PB (provided by the Cancer Treatment Evaluation Program, National Cancer Institute, Bethesda, MD) were dissolved in distilled water (pH 7.4). PAG, p-chloro-PA, and p-iodo-PB were synthesized as described previously (3) . PGD2 and 15-deoxy-{Delta}12,14-PGJ2 were purchased from Cayman Chemical Co. (Ann Arbor, MI) and dissolved in absolute ethanol. G418 was purchased from Life Technologies. PD98059 was from Biomol, Inc. (Plymouth Meeting, PA). CPA was obtained in 10-mg aliquots from Molecular Probes (Eugene, OR).

Cytostasis Assays.
To determine the antiproliferative effects of drugs, cells were seeded at a density of 2 x 104 cells/well in 24-well plates (Costar Co., Cambridge, MA) 24 h prior to the addition of test drugs. On day 5 of the treatment, cells were harvested by trypsinization and counted using a Coulter Counter. The IC50s were determined from dose-response curves.

Northern Blot Analysis.
mRNA was extracted from exponentially growing cells using the Fast Track 2.0 kit (Invitrogen, San Diego, CA). The RNA species were separated on 1.2% agarose-formaldehyde gels and were transferred to a Dura-Lon-UV membrane, UV-cross-linked, and prehybridized and hybridized with [{alpha}-32P]CTP-labeled probes according to the supplier’s instructions (Stratagene, La Jolla, CA). The probes were: hPPAR{gamma}-LBD 1.6 kb cDNA; 1.8 kb XhoI-KpnI fragment of pBKCMVhPPAR{delta}; 0.9 kb BsmI-BamHI fragment of the 3'-end coding sequences of hPPAR{alpha}; a synthetic oligomer complementary to the mouse p21waf1 (23) ; and ß-actin cDNA (Oncor, Gaithersburg, MD). Probes were labeled using a random primed DNA labeling kit (Ready-To-Go; Pharmacia Biotech, Piscataway, NJ), and 50 µCi [32P]CTP (specific activity, 6000 Ci/mmol; DuPont NEN, Boston, MA). Hybridization of the membranes followed the protocol provided by Stratagene for Quick Hyb. Autoradiography was performed using Kodak XAR5 film at -70°C with intensifying screen. For quantification, the relative intensity of signal bands was determined by densitometric analysis of the radiographs.

Gene Transfer and Transactivation Experiments.
Transient expression assays were performed with minor modifications to established methods (24) . Briefly, CV-1 cells were plated in six-well plates at a density of 4 x 104 cells/well in DMEM. Two days later, the medium was changed, and cells were transfected by N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammoniummethyl sulfate (Boehringer Mannheim) with plasmids in the following amounts: 1.4 µg/well of pcDNA-hPPAR{gamma} [hPPAR{gamma}1 (21) in the mammalian expression vector pcDNA] or the empty vector pcDNA (Invitrogen); 0.7 µg/well of pPPRE-3-TK-LUC (a reporter plasmid containing three copies of PPRE of the rat acyl-CoA oxidase promoter upstream the heterologous promoter of thymidine kinase) or empty reporter TK-LUC (a gift from Ron M. Evans, Salk Institute, La Jolla, CA); and 0.3 µg/well of pSV-ß-gal (Promega). After 18–20 h, the medium was again changed, and the ligand/activator drugs were added. Cells were lysed after ~24 h in 300 µl of Promega ß-gal reporter lysis buffer, and supernatants were homogenized and split: 100 µl for the luciferase assay and 150 µl for the Promega ß-gal assay. Luciferase production was assayed according to the standard Analytical Luminescence protocol and measured as light units, normalized for transfection efficiency by ß-gal results expressed as absorbance at 420 according to the Promega ß-gal assay kit. Results from three experiments, each in triplicate, were averaged and expressed as fold activation over the indicated control, with the SD indicated by the error bar, using the Graph Pad (Prism) statistics program.

To obtain stable transformants, MCF7 cells were seeded in 35-mm dishes at a density of 2 x 105 cells/well in 3 ml of growth medium. After 24 h, a DNA mix containing 300 ng of pcDNA-hPPAR{gamma}, 150 ng pSV-neo, and 2 µg of calf thymus carrier DNA were transfected as described above. Forty-eight h after DNA transfections, cells were subcultured in selection medium composed of RPMI 1640 supplemented with 10% FBS, 2 mM L-glutamine, 0.1% penicillin, streptomycin, neomycin antibiotics, and G418 (500 µg/ml). Individual neo-positive colonies were harvested using filter papers presoaked with trypsin, transferred to 24-well plates with G418-containing selection medium.

Ligand Binding Studies.
The binding of PA and derivatives to hPPAR{gamma} was measured using a spectrophometric assay based on the displacement of CPA, as described previously (25) . CPA (1.5 µM) was added to 25 mM Tris-HCl (pH 7.5) at room temperature and scanned against buffer between 312 and 340 nm using a Shimadzu UV-3000 scanning spectrophotometer demonstrating a 319:329-nm ratio of 3. Highly purified recombinant hPPAR{gamma} ligand binding domain (3 µM) was then added to both the sample and reference cuvettes, and the 319:329-nm ratio was determined (~1.2). Subsequently, increasing concentrations of drug were added to both cuvettes, and the 319:329-nm ratio was measured until the 319:329-nm ratio reached a plateau (at around 2.6–2.8). Binding constants were calculated using a single binding site curve fitting with Ultrafit for the Macintosh. The Kds and the SEs derived from 2 to 4 independent experiments are presented in the text.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
PPAR{gamma} Expression Correlates with Tumor Sensitivity to Growth Arrest by PA.
In previous studies, we identified malignant cell lines with varying sensitivity to PA (7) . Of these, cultures of closely related breast carcinoma cell lines, MCF7 and its subclone MCF7ADR, were now used to examine the status of PPAR{gamma}. Consistent with previous findings, PA concentrations required to cause 50% growth arrest at 5 days of treatment were 10.5 and 3.7 mM for MCF7 and MCF7ADR, respectively. Because drug concentrations of up to 4–5 mM can be achieved in humans, MCF7ADR can be defined as a clinically sensitive cell line and MCF7, a resistant one. Northern blot analysis revealed marked differences in the constitutive and PA-induced levels of PPAR{gamma} in these cell lines. Resistant MCF7 cells exhibited low pretreatment levels, which were only slightly up-regulated by PA (<2 fold), whereas the sensitive MCF7ADR had ~5-fold higher base levels of PPAR{gamma}, and these further increased by >=3 fold after 24 h exposure to PA (Fig. 1ACitation ). A similar difference in transcript levels, although less marked, was noted for PPAR{alpha} and {delta} (Fig. 1ACitation ). As would be expected if PPAR{gamma} played a role in cytostasis, the two cell lines also differed in their vulnerability to natural ligands of PPAR{gamma}. Over 90% growth arrest was noted in MCF7ADR cultures treated with either 7 µM of 15-deoxy-{Delta}12,14-PGJ2 or 30 µM PGD2, whereas similar treatments of MC7 cells caused only 55 ± 5% and 37 ± 2% inhibition, respectively. The correlation between PPAR{gamma} expression and PA sensitivity was not limited to the breast carcinoma cells.



View larger version (31K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Expression of PPAR{gamma} in malignant cells with varying sensitivity to PA. Northern blot analysis of mRNA isolated from cells treated with 8 mM PA (+) and untreated controls (-) is shown. A, breast carcinoma MCF7 (resistant) and MCF7ADR (sensitive) cultures were treated with PA for 24 h, and the expression of PPARs was determined by rehybridization of blots to the specific probes. Responsive MCF7ADR cells have higher constitutive and PA-induced levels of PPAR{gamma}, {alpha} and {delta}. With short exposure of the X-ray films (<1 day), only the signal for the short splice variant of PPAR{gamma} (PPAR{gamma}2, 0.65 kb) was evident; the full-length 1.85-kb PPAR{gamma}1 mRNA was visible with longer exposures (not shown). B, glioblastoma U251 (resistant) and A172 (sensitive) cells were treated with PA for 2 and 18 h. Bars, 1.85-kb PPAR{gamma}1 and 0.65-kb PPAR{gamma}2 mRNA. In contrast to the responsive A172, PPAR{gamma} expression was undetectable in the resistant U251 line, even after exposure of films for >1 week. The signal for ß-actin serves as an internal control, indicating the relative amounts of RNA in each lane.

 
A differential expression and up-regulation of the nuclear receptor at baseline and after treatment with PA was noted also in brain cancer cells (Fig. 1BCitation ), specifically in PA-responsive glioblastoma A172 (IC50, 4.6 mM) and the resistant U251 line (IC50, 11.0 mM).

Up-Regulation of PPAR{gamma} by PA Precedes Increases in p21waf1.
To characterize the temporal sequence of drug effect on PPAR{gamma} and its relation to growth arrest, MCF7ADR cultures were treated with PA for various durations of time and examined for expression of the nuclear receptor and of p21waf1, a marker of G1 arrest in these cells (23) . As shown in Fig. 2Citation , PPAR{gamma} levels increased within 9 h of treatment, followed by increases in p21waf1 1 day later. The latter could not be explained by changes in cell density, as evidenced by the low levels of both PPAR{gamma} and p21waf1 transcripts in control cells grown in the absence of drug. The effect of PA on PPAR{gamma} was time dependent (Fig. 2Citation shows up to 90-fold increase after 5 days of treatment), dose dependent (no significant up-regulation noted at <1 mM PA), and reversible upon cessation of treatment (data not shown).



View larger version (36K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Time-dependent changes in PPAR{gamma} and p21waf in PA-treated cells. MCF7ADR cells were exposed to 8 mM PA for the indicated time periods, and their mRNA was subjected to Northern blot analysis. For quantification, the blot was rehybridized with 32P probes for PPAR{gamma}, p21, and ß-actin; the relative intensity of bands was determined by densitometric analysis of the autoradiographs, and the changes in PPAR{gamma} and p21 were corrected for ß-actin. A graphic representation of the relative changes in gene expression occurring during the first 72 h after treatment is shown. Note the earlier rise in PPAR{gamma}, preceding that of p21waf1. After 120 h of treatment, the expression of PPAR{gamma} and p21waf1 increased by about 90- and 20-fold, respectively, over untreated controls.

 
Inhibition of MAP Kinase-mediated Phosphorylation of PPAR{gamma} Increases Tumor Sensitivity to PA.
Although transcriptional activity of nuclear receptors is typically enhanced by phosphorylation, MAP kinase phosphorylation of PPAR{gamma} negatively regulates its function (26) . In an attempt to establish a causal relationship between PPAR activity and tumor cytostasis, PA-resistant MCF7 breast cancer cells with low PPAR{gamma} expression were exposed to PA in the presence of PD98059, an inhibitor of MAP kinase. The combination of 5 µM PD98059 with 5 mM PA resulted in 42 ± 2% decline in the cell proliferation, versus 17 ± 1% for PA alone. By itself, PD98059 had no significant antiproliferative effect (<5%).

Forced Expression of PPAR{gamma} in Resistant Tumor Cells Restores Responsiveness.
To further characterize the correlation between hPPAR{gamma} and antitumor activity, we cotransfected the gene together with a selectable marker (neo) into the PA-resistant MCF7 cells. Stable transformants were selected and tested for PPAR{gamma} expression and their sensitivity to growth arrest by PA. Compared with parental cells, clonal lines 2A/A4 and 1B/A2 were found to have significantly higher baseline and induced levels of PPAR{gamma}; they were also significantly more sensitive to cytostasis by PA (Fig. 3)Citation . The IC50s of the stable transformants were 4.8 mM for 2A/A4 and 5.2 mM for 1B/A2, i.e., essentially the same as for the responsive MCF7ADR line. This was in contrast to MCF7 cells transfected with neo alone: similar to nonresponsive parental cells, the IC50 in clonal line 4C1 was ~10 mM, indicating that changes in PPAR{gamma} expression and sensitivity to cytostasis by PA are not attributable to the process of transfection per se.



View larger version (28K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Forced expression of PPAR{gamma} confers sensitivity to growth arrest by PA. Nonresponsive parental MCF7 and its subclone designated MCF7-PPAR{gamma} (clonal line 2A/A4 cotransfected with pcDNA-hPPAR{gamma} and pSV-neo) were treated for 5 days with the indicated doses of PA. Growth curves (B) show an increased PA sensitivity of MCF7-PPAR{gamma}, similar to that of responsive MCF7ADR cells. In contrast, MCF7 cells transfected with pSV-neo alone (clonal line 4C1, designated MCF7-neo) remained nonresponsive, with IC50 >=10 mM. Bars, SD. A shows PPAR{gamma} expression in the MCF7-PPAR{gamma} and MCF7-neo lines determined by Northern blot analysis of mRNA from cells treated for 24 h with 8 mM PA (+) compared with untreated controls (-). Bars, the 1.85-kb PPAR{gamma}1 and 0.65-kb PPAR{gamma}2 transcripts detected on X-ray films exposed to a hybridized blot for 24 h.

 
Biologically Active Aromatic Fatty Acids Interact with the LBD of PPAR{gamma} and Activate Transcriptional Function.
PA and analogous aromatic fatty acids, but not PAG (a derivative in which the carboxylic acid is blocked), share in common the ability to induce tumor cytostasis and differentiation (see "Introduction"). Because the concentrations required for antitumor activity (mM range) vastly exceed those of common nuclear receptor ligands, we investigated whether they can be considered bona fide ligands of PPAR{gamma}. The interaction with the LBD of the receptor was tested using a spectrophometric assay based on the displacement of CPA from the recombinant hPPAR{gamma}LBD (25) . The aromatic fatty acids were found to bind the nuclear receptor with the following Kds: PA, 5.64 ± 1.8 mM; PB, 3.3 ± 0.9 mM; p-chloro-PA, 2.15 ± 0.5; and p-iodo-PB, 0.23 ± 0.08 mM (Fig. 4)Citation . By contrast, no binding of PAG was noted, even at doses as high as 50 mM. The low affinity of PPAR{gamma} binding corresponds to the potency of aromatic fatty acids as inhibitors of tumor proliferation, i.e., PA < PB < p-chloro- PA < p-iodo-PB. (IC50s in A172 cells are: PA, 4.6 ± 0.6 mM; PB, 1.8 ± 0.2 mM; p-chloro-PA, 1.5 ± 0.2; p-iodo-PB, 0.3 ± 0.04 mM; and PAG >20 mM.)



View larger version (24K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Biologically active aromatic fatty acids bind directly to hPPAR{gamma} LBD. Increasing concentrations of tested drugs were added to cuvettes containing 1.5 µM CPA and 3 µM hPPAR{gamma}. A, PA; B, PB; C, p-chloro-PA (4-ClPA); D, p-iodo-PB (4-IPB); E, PAG. Shown is the relative increase in the 319:329-nm ratio compared with CPA fully bound to PPAR. Each plot is a representative experiment of two to four independent experiments.

 
We next tested for the transactivation of a PPRE-driven reporter gene (luciferase) in a transient expression system. PA, used at pharmacological concentrations required for tumor cytostasis in vitro, increased transcriptional activation capacity of hPPAR{gamma} (Fig. 5)Citation . Within 24 h of treatment with 4 mM PA, luciferase activity increased by 8.5 ± 16–9 fold in cells cotransfected with both pcDNA-hPPAR{gamma} and PPRE3-TK-LUC. By comparison, the natural ligand 15-deoxy-{Delta}12,14- PGJ2 (5 µM) caused 13.5 ± 3 fold activation in these experiments. The modest increases in luciferase seen in cells cotransfected with the reporter PPRE3-TK-LUC and the empty plasmid pcDNA (Fig. 5)Citation is likely attributable to activation of the endogenous PPAR(s) by these drugs. Consistent with their relative potency as ligands, the concentrations of derivatives required to activate PPAR{gamma} to a degree similar to that achieved with 4 mM PA were: PB, 1 mM; p-chloro-PA, 0.5 mM; p-iodo-PB, 0.2 mM; PAG >>10 mM. These findings confirm a high concordance between binding and activation of PPAR{gamma} and tumor cytostasis by the aromatic fatty acids.



View larger version (30K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Transactivation of pPPRE-TK-LUC. The reporter construct contains three copies of the acyl-CoA oxidase PPRE cloned upstream of TK-LUC. CV-1 cell were cotransfected with pcDNA-hPPAR{gamma} and pPPRE-TK-LUC and treated with the 8, 4, and 2 mM PA, as described in "Materials and Methods." The natural ligand 15-deoxy-{Delta}12,14- PGJ2 (15ddPGJ2, 5 µM) served as a positive control. Luciferase activity, normalized to CMX-ßgal, was determined and plotted as fold activation relative to that in cells transfected with the reporter construct alone. The latter served as an endogenous receptor control, because CV-1 cells express significant levels of PPAR{gamma}. Bars, SD.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The PPAR family of nuclear receptors has been the subject of intensive research since the cloning of its first member, PPAR{alpha}, in 1990 (27) . Receptor activation was associated with cell differentiation and regulation of lipid metabolism in a wide spectrum of cell types (19 , 20 , 28 , 29) Quite unexpectedly, PPARs seem to be activated by a wide array of structurally diverse ligands, ranging from prostaglandins and TZDs to fibrates, eicosanoids, nonsteroidal NSAIDs, glucocorticoids, PUFAs, and aromatic fatty acids (19 , 22 , 24 , 30) . Targeting PPARs pharmacologically is thus believed to have implications in the treatment of clinical disorders as diverse as hyperlipidemia, atherosclerosis, hypertension, obesity, diabetes, inflammation, autoimmunity, skin disorders, and cancer.

Exploring the mechanisms of action of aromatic fatty acids, the prototype of which is PA, we first documented a correlation between antitumor activity and the ability of these compounds to activate PPAR{alpha} (19) . Our earlier observations, indicating that PA induces adipocyte differentiation in premalignant fibroblasts (Ref. 1 ; a process depending on PPAR{gamma} activation) and up-regulates PPAR{gamma} in glioma cells (31) , suggested that this PPAR isoform might also mediate tumor cell differentiation. In support of this hypothesis, other groups reported selective tumor cytostasis and differentiation induced by PPAR{gamma} activators such as PGs, TZDs, and PUFAs, observed in cultures of human liposarcoma (32) and various adenocarcinomas (33, 34, 35) . Consistent with the in vitro findings, troglitazone reduced tumor growth in mouse models of prostate (35) and colon (33) cancer without causing any significant toxicity to the host. These studies, however, did not establish a biological role for PPAR{gamma} in the antineoplastic process. In the present report, we address this question focusing on aromatic fatty acids with a low toxicity and anticancer activity in humans (10, 11, 12, 13, 14, 15) .

Our in vitro studies with PA indicate that it up-regulates the expression of PPAR{gamma} in responsive human tumor cells, interacts with the ligand-binding site of the PPAR{gamma} receptor, and activates its transcriptional function. The link between PPAR{gamma} and antitumor activity was documented several ways:

(a) Tumor sensitivity to growth arrest by PA was correlated with pretreatment levels of PPAR{gamma} transcripts in breast carcinoma and glioma cell lines. It is unlikely that this reflects a chance occurrence, because the cells with higher PPAR{gamma} expression were also more vulnerable to cytostasis induced by the natural ligands, 15-deoxy-{Delta}12,14-PGJ2 and PGD2.

(b) Studies carried out in initially resistant cells established that sensitivity to PA can be restored either by forced expression of PPAR{gamma} (gene transfer) or by interfering with receptor phosphorylation through inhibition of MAP kinase, a negative regulator of PPAR{gamma}.

(c) PPAR{gamma} expression increased in responsive cells within the first 9 h of PA treatment, preceding increases in p21waf1, a cyclin-dependent kinase inhibitor associated with G1 arrest in these tumor cells (23) . Receptor binding and activation were common to aromatic fatty acids with antitumor activity and corresponded to their potency as antitumor agents (PA < PB < p-chloro-PA < p-iodo-PB). PAG, a biologically inactive metabolite, failed to bind PPAR{gamma}.

These findings, although not precluding the contribution of other mechanisms (see "Introduction"), establish a tight link between PPAR{gamma} and antitumor activity and provide the first documentation of drugs with selective clinical anticancer activity being identified as ligands of PPAR{gamma}.

The expression of PPAR{gamma} in treated patients is yet to be determined. Of interest are recent studies with PB (a precursor of PA), which show increases in histone acetylation in mononuclear cells of a child with acute promyelocytic leukemia, who achieved complete clinical and cytogenetic remission upon treatment with this drug (15) . Histone acetylation is critical to the function of transcriptional factors, such as the PPARs (36) . The interaction of histone deacetylases with nuclear receptors has been implicated in transcriptional repression. In addition to removing such repression, increases in histone acetylation induced by the aromatic fatty acids can facilitate the binding of nuclear receptors by relaxing specific segments in the tightly coiled DNA. Of note is also the fact that the large doses (20–30 g/day) of the aromatic fatty acids required for therapeutic benefit achieve plasma drug levels in the millimolar range sufficient to activate PPAR{gamma} in vitro. Similar to other PPAR activators, notably the NSAIDs (37) , the metabolic effects seen with PA and PB include sustained decreases in glucose concentrations, hyperammonemia, and symptoms reminiscent of acute hypoglycemia. Elevation in hepatic transaminases has been documented in children (but not in adults) with cancer treated by continuous infusion of PA (38) . Most of these side effects, however, were not dose-limiting and could be controlled by dose reduction. These may belong to and help define a "PPAR activation toxicity syndrome," consistent with the widespread tissue distribution of the receptors.

Earlier studies with PPAR ligands focusing on cancer in rodent models first implicated PPAR{alpha} in hepatocarcinogenesis in rats (39) . More recently, PPAR{gamma} agonists were also shown to promote cancer, specifically of the colon, in genetically susceptible mice (40 , 41) . Such findings raise concerns regarding the carcinogenic potential of PPAR activators in general, several of which are already in wide clinical use (42 , 43) . It must be kept in mind, however, that carcinogenesis by PPAR{alpha} activators has thus far been restricted to rodents, and no significant increase in liver cancer has been noted in patients treated with clofibrate or NSAIDs. The latter may be attributable to the fact that human liver contains a very low level of functional PPAR{alpha}, insufficient to mediate the hyperplastic responses seen in rodents (44) . The promotion of colon cancer by PPAR{gamma} ligands, on the other hand, was described only in susceptible mice harboring a mutated APC gene. To date, no definitive increase in colon cancer has been documented in diabetic patients subjected to chronic treatment with troglitazone, although a nonsignificant increase in gastrointestinal cancer has been reported with clofibrate in large population studies (45) . Continuous use of NSAIDs, on the other hand, lowers the risk of colon cancer in humans (46) . Although the risk posed by PPAR activators to healthy or genetically susceptible humans remains unclear, there is compelling evidence suggesting that PPARs might serve as novel targets for anticancer therapy.

Are the aromatic fatty acids carcinogenic? The safety of PA and PB has been well established in individuals with nonmalignant diseases (urea cycle disorders and ß-chain hemoglobinopathies) who were subjected to chronic treatment with large drug doses (20 or more g/day; Refs. 47, 48, 49 ). No increases in the incidence of cancer were noted in these patient populations. The aromatic fatty acids activate more than one PPAR subtype; it is possible that a specific ratio of activated PPAR isoforms leads to tumor growth arrest, whereas another may induce carcinogenesis in predisposed cells. In this respect, the biological activity of highly specific PPAR ligands remains to be characterized, whereas genetic heterogeneity in the expression of the nuclear receptors may underlie an individual response to dietary and pharmacological agonists.

Should a correlation be established between PPAR expression and antitumor activity in humans, the present in vitro findings may have implications that range from therapeutic guidance to validating a novel target for drug discovery. PPAR{gamma} status may prove to have a predictive value with respect to therapeutic outcome; patient screening on that basis might therefore serve to guide the choice of therapy in a population with severely limited treatment options. Without excluding potential complementation with conventional cytotoxic chemo- and radiotherapy, combination therapy protocols can also be conceived involving the coadministration of aromatic fatty acids with compounds that either target PPARs themselves [e.g., TZDs, PUFAs, and vastatins (50) ] or their heterodimer partner, retinoid X receptor (retinoids). Finally, similar to the evolution of the Her-2/neu oncogene (51) , the tissue distribution and abnormal expression of PPAR{gamma} in cancer cells (46) make it a therapeutic target of choice that could potentially transcend histological categorizations and justify studies to establish the value of PPARs in the molecular profiling of tumors, shifting the basis of therapeutic strategies from their microscopic phenotype to their genotype.


   ACKNOWLEDGMENTS
 
We thank Lei Liu and Nancy Chen for technical assistance.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by funds from the Jefferess Foundation, Grant R21-CA69848 from the NIH (to D. S.), and Grant BBSRC ROPA Award MOLO4650 (to C. N. A. P.). Back

2 To whom requests for reprints should be addressed, at University of Virginia Health Sciences Center, Jordan Annex, Box 513, Lane Road, Room 2229, Charlottesville, VA 22908. Phone: (973) 562-3501; Fax: (973) 562-3629. Back

3 The abbreviations used are: PA, phenylacetate; PB, phenylbutrate; PPAR, peroxisome proliferator-activated receptor; hPPAR, human PPAR; PPRE, PPAR response element; PAG, phenylacetylglutamine; PGD2, prostaglandin D2; PGJ2, prostaglandin J2; CPA, cis-parinaric acid; ß-gal, ß-galactosidase; MAP, mitogen-activated protein; LBD, ligand-binding domain; TZD, thiazolidinedione; NSAID, nonsteroidal anti-inflammatory drug; PUFA, polyunsaturated fatty acid. Back

4 T. E. Witzig, personal communication.

Received 8/17/99; revised 12/ 7/99; accepted 12/ 8/99.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Samid D., Shack S., Sherman L. T. Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res., 52: 1988-1992, 1992.[Abstract/Free Full Text]
  2. Samid D., Hudgins W. R., Shack S., Liu L., Prasanna P., Myers C. E. Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. Adv. Exp. Med. Biol., 400A: 501-505, 1997.
  3. Hudgins W. R., Shack S., Myers C. E., Samid D. Cytostatic activity of phenylacetate and derivatives against tumor cells. Correlation with lipophilicity and inhibition of protein prenylation. Biochem. Pharmacol., 50: 1273-1279, 1995.[CrossRef][Medline]
  4. Liu L., Shack S., Stetler-Stevenson W. G., Hudgins W. R., Samid D. Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate. J. Investig. Dermatol., 103: 335-340, 1994.[CrossRef][Medline]
  5. Call T. G., Stenson M. J., Witzig T. E. Effects of phenylacetate on cells from patients with B-chronic lymphocytic leukemia. Leuk. Lymphoma, 14: 145-149, 1994.[Medline]
  6. Carducci M. A., Nelson J. B., Chan-Tack K. M., Ayyagari S. R., Sweatt W. S., Campbell P. A., Nelson W. G., Simons J. W. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin. Cancer Res., 2: 379-387, 1996.[Abstract/Free Full Text]
  7. Shack S., Miller A., Liu L., Prasanna P., Thibault A., Samid D. Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate. Clin. Cancer Res., 2: 865-872, 1996.[Abstract]
  8. Gore S. D., Samid D., Weng L. J. Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation and apoptosis of primary neoplastic myeloid cells. Clin. Cancer Res., 3: 1755-1762, 1997.[Abstract]
  9. Thibault A., Cooper M. R., Figg W. D., Venzon D. J., Sartor A. O., Tompkins A. C., Weinberger M. S., Headlee D. J., McCall N. A., Samid D., Myers C. E. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res., 54: 1690-1694, 1994.[Abstract/Free Full Text]
  10. Thibault A., Samid D., Cooper M. R., Figg W. D., Tompkins A. C., Patronas N., Headlee D. J., Kohler D. R., Venzon D. J., Myers C. E. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer (Phila.), 75: 2932-2938, 1995.[CrossRef][Medline]
  11. Prados M. D., Spence A., Schold C., Robbins I., Mehta M. M., Berger M., Kuhn J., Rector J., Chang S., Gilbert M. A Phase II trial of phenylacetic acid for recurrent glioma. Preliminary report of the North American Brain Tumor Consortium. Proc. Am. Soc. Clin. Oncol., 15: A288 1996.
  12. Thibault A., Figg W. D., Samid D. A Phase I study of the differentiating agent phenylbutyrate in patents with cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol., 15: A1539 1996.
  13. Carducci M., Bowling M. K., Eisenberger M., Sinibaldi V., Chen T., Noe D., Grochow L., Donehower R. Phenylbutyrate (PB) for refractory solid tumors: Phase I clinical and pharmacological evaluation of intravenous and oral PB. Anticancer Res., 17: 3972-3973, 1997.
  14. Gore S. D., Miller C. B., Weng L-J., Burks K., Griffin C. A., Chen T. L., Smith V., Burke P. J., Grever M., Rowinsky E. K. Clinical development of sodium phenylbutyrate (SPB) as a putative differentiating agent in myeloid malignancies. Anticancer Res., 17: 3981-3982, 1997.
  15. Warrell R. P., He L-Z., Richon V., Calleja E., Pandolfi P. P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst., 90: 1621-1625, 1998.[Abstract/Free Full Text]
  16. Samid D., Ram Z., Hudgins W. R., Shack S., Liu L., Walbridge S., Oldfield E. H., Myers C. E. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res., 54: 891-895, 1994.[Abstract/Free Full Text]
  17. Lea M. A., Randolph V. M. Induction of reporter gene expression by inhibitors of histone deacetylase. Anticancer Res., 18: 2717-2721, 1998.[Medline]
  18. Prasanna P., Shack S. W. V. L., Samid D. Phenylacetate in chemoprevention: in vitro and in vivo suppression of 5-aza-2'-deoxycytidine-induced carcinogenesis. Clin. Cancer Res., 1: 865-871, 1995.[Abstract]
  19. Pineau T., Hudgins W. R., Liu L., Chen L. C., Sher T., Gonzalez F. J., Samid D. Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem. Pharmacol., 52: 659-667, 1996.[CrossRef][Medline]
  20. Tugwood J. D., Aldridge T. C., Lambe K. G., Macdonald N., Woodyatt N. J. Peroxisome proliferator-activated receptors: structures and function. Ann. NY Acad. Sci., 804: 252-265, 1996.[Medline]
  21. Greene M. E., Blumberg B., McBride O. W., Yi H. F., Kronquist K., Kwan K., Hsieh L., Greene G., Nimer S. D. Isolation of the human peroxisome proliferator activated receptor {gamma} cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr., 4: 281-299, 1995.[Medline]
  22. Spiegelman B. M. PPAR-{gamma}–adipogenic regulator and thiazolidinedione receptor. Diabetes, 47: 507-514, 1998.[Abstract]
  23. Gorospe M., Shack S., Guyton K. Z., Samid D., Holbrook N. J. Up-regulation and functional role of p21Waf1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate. Cell Growth Differ., 7: 1609-1615, 1996.[Abstract]
  24. Kliewer S. A., Sundseth S. S., Jones S. A., Brown P. J., Wisely G. B., Koble C. S., Devchand P., Wahli W., Willson T. M., Lenhard J. M., Lehmann J. M. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors {alpha} and {gamma}. Proc. Natl. Acad. Sci. USA, 94: 4318-4323, 1997.[Abstract/Free Full Text]
  25. Palmer C. N. A., Wolf C. R. cis-Parinaric acid is a ligand for the human peroxisome proliferator activated receptor {gamma}-development of a novel spectrophotometric assay for the discovery of PPAR-{gamma} ligands. FEBS Lett., 431: 476-480, 1998.[CrossRef][Medline]
  26. Camp H. S., Tafuri S. R. Regulation of peroxisome proliferator-activated receptor {gamma} activity by mitogen-activated protein kinase. J. Biol. Chem., 272: 10811-10816, 1997.[Abstract/Free Full Text]
  27. Issemann I., Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators [see comments]. Nature (Lond.), 347: 645-650, 1990.[CrossRef][Medline]
  28. Vidal-Puig, A. J., Considine, R. V., Jimenez-Linan, M., Werman, A., Pories, W. J., Caro, J. F., and Flier, J. S. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Investig., 99: 2416–2422, 1997.
  29. Jiang C. Y., Ting A. T., Seed B. PPAR-{gamma} agonists inhibit production of monocyte inflammatory cytokines. Nature (Lond.), 391: 82-86, 1998.[CrossRef][Medline]
  30. Forman B. M., Chen J., Evans R. M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors {alpha} and {delta}. Proc. Natl. Acad. Sci. USA, 94: 4312-4317, 1997.[Abstract/Free Full Text]
  31. Samid D., Kulkarni M., Liu L., Thibault A. The nuclear receptors, PPAR{alpha} and PPAR{gamma}, are molecular targets of the differentiation inducers phenylacetate and phenylbutyrate. Proc. Annu. Meet. Am. Assoc. Cancer Res., 38: A3024 1997.
  32. Tontonoz P., Singer S., Forman B. M., Sarraf P., Fletcher J. A., Fletcher C. D., Brun R. P., Mueller E., Altiok S., Oppenheim H., Evans R. M., Spiegelman B. M. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor {gamma} and the retinoid X receptor. Proc. Natl. Acad. Sci. USA, 94: 237-241, 1997.[Abstract/Free Full Text]
  33. Sarraf P., Mueller E., Jones D., King F. J., Deangelo D. J., Partridge J. B., Holden S. A., Chen L. B., Singer S., Fletcher C., Spiegelman B. M. Differentiation and reversal of malignant changes in colon cancer through PPAR-{gamma}. Nat. Med., 4: 1046-1052, 1998.[CrossRef][Medline]
  34. Mueller E., Sarraf P., Tontonoz P., Evans R. M., Martin K. J., Zhang M., Fletcher C., Singer S., Spiegelman B. M. Terminal differentiation of human breast cancer through PPAR-{gamma}. Mol. Cell, 1: 465-470, 1998.[CrossRef][Medline]
  35. Kubota T., Koshizuka K., Williamson E. A., Asou H., Said J. W., Holden S., Miyoshi I., Koeffler H. P. Ligand for peroxisome proliferator-activated receptor {gamma} (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res., 58: 3344-3352, 1998.[Abstract/Free Full Text]
  36. Heinzel T., Lavinsky R. M., Mullen T. M., Soderstrom M., Laherty C. D., Torchia J., Yang W. M., Brard G., Ngo S. D., Davie J. R., Seto E., Eisenman R. N., Rose D. W., Glass C. K., Rosenfeld M. G. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression [see comments]. Nature (Lond.), 387: 43-48, 1997.[CrossRef][Medline]
  37. Gilman, A. G., Rall, T. W., Nies, A. S., and Taylor, P. Goodman and Gilman’s the Pharmacological Basis of Therapeutics, Ed. 8. Oxford: Pergamon Press, 1990.
  38. Serabe B., Adamson P., Wolfe R., Balis F., Packer R., Aleksic A., Jakacki R., Blaney S. Phase I trial and pharmacokinetic (PK) study of phenylacetate (PA) given as a 28-day continuous infusion (CIVI) in children. Proc. Am. Assoc. Cancer Res., 38: A661 1997.
  39. Green S. Peroxisome proliferators: a model for receptor mediated carcinogenesis. Cancer Surv., 14: 221-232, 1992.[Medline]
  40. Lefebvre A. M., Chen I. H., Desreumaux P., Najib J., Fruchart J. C., Geboes K., Briggs M., Heyman R., Auwerx J. Activation of the peroxisome proliferator-activated receptor {gamma} promotes the development of colon tumors in C57bl/6j-Apc(Min)/+ mice. Nat. Med., 4: 1053-1057, 1998.[CrossRef][Medline]
  41. Saez E., Tontonoz P., Nelson M. C., Alvarez J. G. A., Ming U. T., Baird S. M., Thomazy V. A., Evans R. M. Activators of the nuclear receptor PPAR-{gamma} enhance colon polyp formation. Nat. Med., 4: 1058-1061, 1998.[CrossRef][Medline]
  42. Seed B. PPAR-{gamma} and colorectal carcinoma–conflicts in a nuclear family. Nat. Med., 4: 1004-1005, 1998.[CrossRef][Medline]
  43. Cattley R. C., Deluca J., Elcombe C., Fennercrisp P., Lake B. G., Marsman D. S., Pastoor T. A., Popp J. A., Robinson D. E., Schwetz B., Tugwood J., Wahli W. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans. Regul. Toxicol. Pharmacol., 27: 47-60, 1998.
  44. Palmer C. N., Hsu M. H., Griffin K. J., Raucy J. L., Johnson E. F. Peroxisome proliferator activated receptor-{alpha} expression in human liver. Mol. Pharmacol., 53: 14-22, 1998.[Abstract/Free Full Text]
  45. Oliver M. F., Heady J. A., Morris J. N., Cooper M. J. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br. Heart J., 40: 1069-1118, 1978.[Free Full Text]
  46. DuBois R. N., Gupta R., Brockman J., Reddy B. S., Krakow S. L., Lazar M. A. The nuclear eicosanoid receptor PPAR{gamma} is aberrantly expressed in colonic cancers. Carcinogenesis (Lond.), 19: 49-53, 1998.[Abstract/Free Full Text]
  47. Simell O., Sipila I., Rajantie J., Valle D. L., Brusilow S. W. Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance. Pediatr. Res., 20: 1117-1121, 1986.[Medline]
  48. Dover G. J., Brusilow S., Charache S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood, 84: 339-343, 1994.[Abstract/Free Full Text]
  49. Olivieri N. F., Rees D. C., Ginder G. D., Thein S. L., Brittenham G. M., Waye J. S., Weatherall D. J. Treatment of thalassaemia major with phenylbutyrate and hydroxyurea. Lancet, 350: 491-492, 1997.[CrossRef][Medline]
  50. Prasanna P., Thibault A., Liu L., Samid D. Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J. Neurochem., 66: 710-716, 1996.[Medline]
  51. Bookman M. A. Biological therapy of ovarian cancer: current directions. Semin. Oncol., 25: 381-396, 1998.[Medline]



This article has been cited by other articles:


Home page
 J. Bacteriol.Home page
R. J. Law, J. N. R. Hamlin, A. Sivro, S. J. McCorrister, G. A. Cardama, and S. T. Cardona
A Functional Phenylacetic Acid Catabolic Pathway Is Required for Full Pathogenicity of Burkholderia cenocepacia in the Caenorhabditis elegans Host Model
J. Bacteriol., November 1, 2008; 190(21): 7209 - 7218.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. M. Hasan, M. J. Longacre, S. W. Stoker, T. Boonsaen, S. Jitrapakdee, M. A. Kendrick, J. C. Wallace, and M. J. MacDonald
Impaired Anaplerosis and Insulin Secretion in Insulinoma Cells Caused by Small Interfering RNA-mediated Suppression of Pyruvate Carboxylase
J. Biol. Chem., October 17, 2008; 283(42): 28048 - 28059.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
P. Tanmahasamut, J. Liu, L. B. Hendry, and N. Sidell
Conjugated Linoleic Acid Blocks Estrogen Signaling in Human Breast Cancer Cells
J. Nutr., March 1, 2004; 134(3): 674 - 680.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. Kopelovich, J. R. Fay, R. I. Glazer, and J. A. Crowell
Peroxisome Proliferator-activated Receptor Modulators As Potential Chemopreventive Agents
Mol. Cancer Ther., March 1, 2002; 1(5): 357 - 363.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Han, R. K. Wada, and N. Sidell
Differentiation of Human Neuroblastoma by Phenylacetate Is Mediated by Peroxisome Proliferator-activated Receptor {{gamma}}
Cancer Res., May 1, 2001; 61(10): 3998 - 4002.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
D. Artemov, M. Solaiyappan, and Z. M. Bhujwalla
Magnetic Resonance Pharmacoangiography to Detect and Predict Chemotherapy Delivery to Solid Tumors
Cancer Res., April 1, 2001; 61(7): 3039 - 3044.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
R. Pili, M. P. Kruszewski, B. W. Hager, J. Lantz, and M. A. Carducci
Combination of Phenylbutyrate and 13-cis Retinoic Acid Inhibits Prostate Tumor Growth and Angiogenesis
Cancer Res., February 1, 2001; 61(4): 1477 - 1485.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Samid, D.
Right arrow Articles by Thibault, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Samid, D.
Right arrow Articles by Thibault, A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research